INTERVENTIONALRECRUITINGNCT07434895

The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-08-12

What this record can show

Protocol only - no registry results posted

This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.

Registry facts

Study at a glance

Phase: EARLY PHASE1
Enrollment: 23 (ESTIMATED)
Start date: 2026-08-05
Sponsor: Hannah Harris
Design: RANDOMIZED · CROSSOVER · BASIC SCIENCE
Locations: 1
Results record: Not present in registry snapshot

Linked local records

Related local records

Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.

Conditions

No published condition report matched.

Cannabinoids and active compounds

cannabidiol

Medicines

No exact medicine-name link was found.

Interventions

What was registered

DRUG

Cannabidiol, Medium Dose

Active Cannabidiol: Active cannabidiol (medium dose) will be administered orally for 14 days.

DRUG

Cannabidiol, Higher Dose

Description: Active Cannabidiol: Active cannabidiol (higher dose) will be administered orally for 14 days.

DRUG

Active Inhaled Cannabis

Active Marijuana: Active Marijuana (active inhaled cannabis) will be administered through a vaporizer once per study session day (Day 1, 7, 14) per block (3 blocks total).

DRUG

Placebo Cannabidiol

Inactive/Placebo Cannabidiol: Inactive/placebo cannabidiol will be administered orally for 14 days.

DRUG

Placebo Inhaled Cannabis

Inactive/Placebo Marijuana: Experimental, non-therapeutic administration of an inactive/placebo marijuana dose will be administered through a vaporizer at each study session day (Days 1, 7, 14) per block (3 blocks total).

Eligibility

Population and criteria

Sex: ALL
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepted

Inclusion criteria

English-speaking, literate adults,
Male or female,
Between the ages of 18-55,
Body Mass Index from 18.5-32.0 kg/m2,
Not currently seeking treatment for cannabis or drug use,
Able to provide written informed consent and perform all study procedures,
If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.

Exclusion criteria

Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \[e.g., asthma, COPD\]),
Current or past history of major psychiatric disorder that would limit ability to participate in the study,
Use of cannabis exclusively for medical reasons (no recreational use reported),
Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
Clinically significant abnormal ECG (as determined by study physician/cardiologist),
Clinically significant abnormal laboratory findings,
History of seizure disorder,
Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).

primary outcomes

primary measures

Change from Baseline-Subject-Related Outcome-VAS Drug Liking

Time frame: Days 1 (baseline), 7, 14, prior to and in regular intervals after drug administration for the duration of the session (approx. 8 hours per session).

Participants rated their subjective drug liking on a standardized VAS scale (0 to 100). These Scores will indicate how participants are feeling at that moment, including questions on mood, physical symptoms, and drug effects. Low scores mean little to no drug liking. Higher scores mean greater drug liking. Raw data transformed to peak scores.

Change from Baseline-Marijuana Purchase Task: Elasticity

Time frame: Days 1 (baseline), 7, 14, measured ~3 hours post cannabis administration.

Behavioral economic demand for cannabis: how much a participant values cannabis as its "price" (cost, effort, or availability) increases. Participants indicate how much marijuana they would buy and consume at increasing, hypothetical prices. This outcome describes how sensitive marijuana consumption is to price changes and how quickly demand decreases as marijuana becomes more expensive.

secondary outcomes

secondary measures

Change from Baseline-Cold Pressor Test (CPT) Threshold

Time frame: Days 1 (baseline), 7, 14, This outcome will be recorded before and at two additional intervals after active and placebo cannabis administration during the laboratory session (a total of 6 measurements per session).

Participants first immerse a dominant hand into the warm-water bath for 2 minutes. The participants are then instructed to immerse the dominanat hand in the cold-water bath and report when pain is first experienced, and to keep the hand submerged as long as possible, and to withdraw the hand from the water when the sensation becomes uncomfortable. Latency (in seconds) to first pain sensations (threshold) will be measured and recorded.

Change from Baseline-Cold Pressor Test (CPT) Tolerance

Participants first immerse a dominant hand into the warm-water bath for 2 minutes. The participants are then instructed to immerse the dominant hand in the cold-water bath and report when pain is first experienced, and to keep the hand submerged as long as possible, and to withdraw the hand from the water when the sensation becomes uncomfortable. Latency to withdrawal from the water (tolerance) will be measured and recorded.

Change from Baseline-Cold Pressor Visual Analog Scale (CPT-VAS): Painful

Time frame: Days 1 (baseline), 7, 14, This outcome will be recorded before and after the CPT for a total of 6 measurements per session.

Participants first immerse a dominant hand in the warm-water bath for 2 minutes. The participants are then instructed to immerse the dominant hand in the cold-water bath and report when pain is first experienced, and to keep the hand submerged as long as possible, and to withdraw the hand from the water when the sensation becomes uncomfortable. Participants will report how painful the pain was on a visual analog scale. Low scores mean little to no pain. Higher scores mean greater pain. Raw data transformed to peak scores.

Publications

Locally readable linked articles

No exact PMID-linked public article is currently readable locally.

Snapshot provenance

Snapshot: add2633b-0fbd-40e9-bf67-3e61947d338d
Retrieved: 11/09/2026, 14:14:59
SHA-256: 62bf5028a7c610debe976a7db9af2a954581981364f285b9e6ed3dcd84dcfd60